Seroatlas · Human Serome Atlas

AASS

Alpha-aminoadipic semialdehyde synthase, mitochondrial

Also known as: AASS_HUMAN, LKRSDH, LORSDH

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
Q9UDR5
Gene
AASS
Ensembl
ENSG00000008311
Chromosome
7
Canonical length
926 aa
Protein class
Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Potential drug targets, Predicted intracellular proteins
Subcellular location
Nucleoplasm,Vesicles,Mitochondria
Quaternary structure
Homotetramer

OverviewNCBI Gene

This gene encodes a bifunctional enzyme that catalyzes the first two steps in the mammalian lysine degradation pathway. The N-terminal and the C-terminal portions of this enzyme contain lysine-ketoglutarate reductase and saccharopine dehydrogenase activity, respectively, resulting in the conversion of lysine to alpha-aminoadipic semialdehyde. Mutations in this gene are associated with familial hyperlysinemia. [provided by RefSeq, Jul 2008]

Canonical amino-acid sequenceUniProt

926 residues, UniProt reviewed canonical sequence.

>Q9UDR5|AASS
     1  MLQVHRTGLG RLGVSLSKGL HHKAVLAVRR EDVNAWERRA PLAPKHIKGI TNLGYKVLIQ
    61  PSNRRAIHDK DYVKAGGILQ EDISEACLIL GVKRPPEEKL MSRKTYAFFS HTIKAQEANM
   121  GLLDEILKQE IRLIDYEKMV DHRGVRVVAF GQWAGVAGMI NILHGMGLRL LALGHHTPFM
   181  HIGMAHNYRN SSQAVQAVRD AGYEISLGLM PKSIGPLTFV FTGTGNVSKG AQAIFNELPC
   241  EYVEPHELKE VSQTGDLRKV YGTVLSRHHH LVRKTDAVYD PAEYDKHPER YISRFNTDIA
   301  PYTTCLINGI YWEQNTPRLL TRQDAQSLLA PGKFSPAGVE GCPALPHKLV AICDISADTG
   361  GSIEFMTECT TIEHPFCMYD ADQHIIHDSV EGSGILMCSI DNLPAQLPIE ATECFGDMLY
   421  PYVEEMILSD ATQPLESQNF SPVVRDAVIT SNGTLPDKYK YIQTLRESRE RAQSLSMGTR
   481  RKVLVLGSGY ISEPVLEYLS RDGNIEITVG SDMKNQIEQL GKKYNINPVS MDICKQEEKL
   541  GFLVAKQDLV ISLLPYVLHP LVAKACITNK VNMVTASYIT PALKELEKSV EDAGITIIGE
   601  LGLDPGLDHM LAMETIDKAK EVGATIESYI SYCGGLPAPE HSNNPLRYKF SWSPVGVLMN
   661  VMQSATYLLD GKVVNVAGGI SFLDAVTSMD FFPGLNLEGY PNRDSTKYAE IYGISSAHTL
   721  LRGTLRYKGY MKALNGFVKL GLINREALPA FRPEANPLTW KQLLCDLVGI SPSSEHDVLK
   781  EAVLKKLGGD NTQLEAAEWL GLLGDEQVPQ AESILDALSK HLVMKLSYGP EEKDMIVMRD
   841  SFGIRHPSGH LEHKTIDLVA YGDINGFSAM AKTVGLPTAM AAKMLLDGEI GAKGLMGPFS
   901  KEIYGPILER IKAEGIIYTT QSTIKP

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against AASS can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Intracellular
Secreted
No
Transmembrane segments
0
Mean surface accessibility (rSASA)
0.24
Highest tissue expression
47 nTPM

Expression across tissuesHPA

Tissue

  • liver: 47 nTPM
  • ovary: 45 nTPM
  • choroid plexus: 23 nTPM
  • blood vessel: 19 nTPM
  • fallopian tube: 19 nTPM
  • pancreas: 18 nTPM

Single-cell type

  • hepatocytes: 392 nCPM
  • schwann cells: 296 nCPM
  • ovarian stromal cells: 273 nCPM
  • bergmann glia: 251 nCPM
  • thymic myoid cells: 223 nCPM
  • astrocytes: 211 nCPM

Immune cell

  • memory B-cell: 0.1 nTPM
  • T-reg: 0.1 nTPM
  • basophil: 0 nTPM
  • classical monocyte: 0 nTPM
  • eosinophil: 0 nTPM
  • gdT-cell: 0 nTPM

Brain region

  • choroid plexus: 19 nTPM
  • basal ganglia: 12 nTPM
  • white matter: 11 nTPM
  • medulla oblongata: 11 nTPM
  • midbrain: 9.9 nTPM
  • thalamus: 9.6 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about AASS.

Disease | AllUniProt

Conditions AASS is implicated in, by any mechanism.

Disease | GeneticClinVar

23 pathogenic / likely-pathogenic of 315 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
0.81
gnomAD pLI
0
gnomAD missense Z
0.88
DepMap mean gene effect
0.02
DepMap dependency class
selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 6% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

  • histone binding
  • transcription corepressor activity
  • saccharopine dehydrogenase (NAD+, L-glutamate-forming) activity
  • saccharopine dehydrogenase (NAD+, L-lysine-forming) activity
  • saccharopine dehydrogenase (NADP+, L-lysine-forming) activity
  • saccharopine dehydrogenase activity

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads AASS as an antibody target. Whether an autoantibody or antibody against AASS could matter depends on whether native AASS is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

AASS is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label AASS as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/AASS. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

Loading the interactive Seroatlas protein explorer...